279 related articles for article (PubMed ID: 34003702)
21. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
22. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
Eifel P; Axelson JA; Costa J; Crowley J; Curran WJ; Deshler A; Fulton S; Hendricks CB; Kemeny M; Kornblith AB; Louis TA; Markman M; Mayer R; Roter D
J Natl Cancer Inst; 2001 Jul; 93(13):979-89. PubMed ID: 11438563
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy for treating locoregional recurrence in women with breast cancer.
Rauschecker H; Clarke M; Gatzemeier W; Recht A
Cochrane Database Syst Rev; 2001; 2001(4):CD002195. PubMed ID: 11687148
[TBL] [Abstract][Full Text] [Related]
24. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
25. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
26. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
27. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.
Crichton ML; Aliberti S; Chalmers JD
Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30872400
[TBL] [Abstract][Full Text] [Related]
29. Controversies in design and interpretation of adjuvant clinical trials.
Cuzick J
Cancer Invest; 2010; 28 Suppl 1():28-34. PubMed ID: 20653405
[TBL] [Abstract][Full Text] [Related]
30. Axillary treatment for operable primary breast cancer.
Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
[TBL] [Abstract][Full Text] [Related]
31. Validation of novel imaging methodologies for use as cancer clinical trial end-points.
Sargent DJ; Rubinstein L; Schwartz L; Dancey JE; Gatsonis C; Dodd LE; Shankar LK
Eur J Cancer; 2009 Jan; 45(2):290-9. PubMed ID: 19091547
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer CE; Blum JL; Yothers G; Asmar L; Flynn PJ; Robert NJ; Hopkins JO; O'Shaughnessy JA; Rastogi P; Puhalla SL; Hilton CJ; Dang CT; Gómez HL; Vukelja SJ; Lyss AP; Paul D; Brufsky AM; Colangelo LH; Swain SM; Mamounas EP; Wolmark N
J Clin Oncol; 2024 Apr; 42(12):1344-1349. PubMed ID: 38335467
[No Abstract] [Full Text] [Related]
34. Antigen-specific active immunotherapy for ovarian cancer.
Paijens ST; Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; de Bruyn M; Nijman HW
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD007287. PubMed ID: 30199097
[TBL] [Abstract][Full Text] [Related]
35. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
36. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
37. Is immediate imaging important in managing low back pain?
Andersen JC
J Athl Train; 2011; 46(1):99-102. PubMed ID: 21214357
[TBL] [Abstract][Full Text] [Related]
38. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
39. Oncoplastic breast-conserving surgery for women with primary breast cancer.
Nanda A; Hu J; Hodgkinson S; Ali S; Rainsbury R; Roy PG
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013658. PubMed ID: 34713449
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
